Probiotics — live microorganisms that, when administered in adequate amounts, confer a health benefit on the host — have become one of the most commercially significant ingredient categories in the global supplement and functional food markets. But regulatory complexity and a widening gap between marketing claims and scientific evidence demand careful navigation.
The Microbiome as a Therapeutic Target
The human gut microbiome — comprising approximately 38 trillion microbial cells representing over 1,000 species — is now understood to be a dynamic, trainable ecosystem with profound influence on immune development, metabolic function, brain signalling via the gut-brain axis, and resistance to pathogen colonisation. The therapeutic potential of modulating this ecosystem through diet, prebiotics, and probiotics is one of the most active areas of biomedical research globally.
Human clinical trials have established efficacy for specific probiotic strains in well-defined indications: Lactobacillus rhamnosus GG for reducing the duration of acute infectious diarrhoea and antibiotic-associated diarrhoea; Saccharomyces boulardii for Clostridioides difficile-associated colitis prevention; Bifidobacterium infantis 35624 for IBS symptom reduction. These are strain-specific, dose-dependent effects — they do not generalise to “probiotics” as a class.
Strain Specificity: Why It Matters
Probiotic effects are strain-specific — meaning that clinical outcomes established for L. rhamnosus GG cannot be extrapolated to other Lactobacillus species or even to other L. rhamnosus strains. This is a fundamental principle that is frequently violated in supplement marketing. Formulations should be judged on the evidence for the specific strain(s) used, at the specific dose studied, in the specific population of interest.
The EU has not authorised any health claims for probiotic bacteria under Regulation (EC) No 1924/2006, principally because the European Food Safety Authority (EFSA) determined that applicants had not adequately characterised the microorganism and its relation to the claimed effect. This does not mean probiotics are ineffective — it means that the existing regulatory framework requires a level of strain-specific substantiation that few applications have met.
Product Quality and Viability
Probiotic viability at end of shelf life is a key quality criterion and a frequent source of consumer disappointment. The labelled CFU count must be supported by stability data demonstrating survival through the product’s stated shelf life under recommended storage conditions. Moisture, heat, and oxygen are the primary enemies of probiotic stability; encapsulation technologies — including microencapsulation, enteric coating, and lyophilisation — substantially improve survival both in the product and through gastric transit.
Third-party testing against ISO 19344:2015 (or equivalent) provides independent verification of viable cell counts and identity, and is increasingly expected by retailers and regulators. At Makrolife Biotech, we support probiotic supplement brands with ISO 17025-accredited microbiological testing, safety assessment, and full PIF documentation.